{"id":"NCT01335399","sponsor":"Bristol-Myers Squibb","briefTitle":"Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma","officialTitle":"A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-08-04","primaryCompletion":"2019-10-01","completion":"2021-09-03","firstPosted":"2011-04-14","resultsPosted":"2020-10-22","lastUpdate":"2022-09-30"},"enrollment":748,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"Lenalidomide","otherNames":["Revlimid®"]},{"type":"DRUG","name":"Dexamethasone","otherNames":["Decadron®","Dexamethasone Intensol®","Dexpak®","Taperpak®"]},{"type":"DRUG","name":"Dexamethasone","otherNames":["Decadron®","Dexamethasone Intensol®","Dexpak®","Taperpak®"]},{"type":"DRUG","name":"Dexamethasone","otherNames":["Decadron®","Dexamethasone Intensol®","Dexpak®","Taperpak®"]},{"type":"DRUG","name":"Dexamethasone","otherNames":["Decadron®","Dexamethasone Intensol®","Dexpak®","Taperpak®"]},{"type":"BIOLOGICAL","name":"Elotuzumab (BMS-901608; HuLuc63)","otherNames":[]},{"type":"BIOLOGICAL","name":"Elotuzumab (BMS-901608; HuLuc63)","otherNames":[]}],"arms":[{"label":"Lenalidomide + Dexamethasone","type":"ACTIVE_COMPARATOR"},{"label":"Lenalidomide + Dexamethasone + Elotuzumab","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS)","primaryOutcome":{"measure":"Progression-Free Survival (PFS)","timeFrame":"From randomization to date of first documented tumor progression or death due to any cause (up to 8 years)","effectByArm":[{"arm":"E-Ld Cohort","deltaMin":31.38,"sd":null},{"arm":"Ld Cohort","deltaMin":29.47,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.4358"},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":5},"locations":{"siteCount":235,"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","Germany","Greece","Hungary","Ireland","Israel","Italy","Poland","Puerto Rico","Romania","Russia","Spain","Switzerland","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["35550060"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsstudyconnect.com/s/US/English/USenHome","https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":293,"n":371},"commonTop":["Diarrhoea","Fatigue","Oedema peripheral","Anaemia","Constipation"]}}